Cargando…

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis

Ruxolitinib is the first Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis, where its efficacy is often associated with cytopenia. It is possible that the severity of cytopenia is in part driven by C (max). A once‐daily sustained‐release (SR) formulation of ruxolitinib was the...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Yeleswaram, Swamy, Hou, Kevin, Chen, Xuejun, Erickson‐Viitanen, Sue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221065/
https://www.ncbi.nlm.nih.gov/pubmed/30105794
http://dx.doi.org/10.1002/hon.2544